65,437 trials
Non-allergic Rhinitis
Primary: Runny Nose as Measured by the Visual Analog Scale (VAS) at Baseline — 6.07 score on a scale
Metabolic Acidosis · Chronic Kidney Disease · Cognitive Dysfunction
Primary: Change in Cognitive Function Composite Score at 12 Months — 52.3; 47.3; 53.5; 49.3 T-score
Stroke · Stroke Sequelae · Depression
Primary: Change in Cognition as Assessed by the Montreal Cognitive Assessment Score — 23.5; 22.5; 25.5; 23.7 score on a scale
Dementia
Primary: Provider Recruitment Feasibility — 1.44 Providers trained per month
Influenza
Primary: Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) — 50; 27; 53; 18 Participants
Cerebral Palsy
Primary: Feasibility: Number of Days to Meet Target Enrollment Size — 56; 29; 129 Days
Insomnia
Primary: Insomnia Severity Index (ISI) — 15.9; 15.4; 12.7; 11.6 score on a scale — p=0.001
Rabies
Primary: Number of Participants Who Experienced a Local Solicited Adverse Event (AE) Post Dose 1 (Day 1) — 13; 15; 10; 5 Participants
Hypertension · Prehypertension
Primary: Resting Systolic Blood Pressure — 129.5; 127.9; 124.3; 123.6 mm Hg
Cesarean Section
Primary: Time to First Narcotic Rescue Dose in the First 24 Hours Post-cesarean Delivery. — NA; 23.5 hours
Non-small Cell Lung Cancer (NSCLC)
Primary: Evaluate Local Tumor Control With Individually-optimized Stereotactic Ablative Radiotherapy (SABR) for Lung Tumors. — 34; 70; 60; 15 lesions
Locally Advanced or Metastatic Renal Cell Carcinoma
Primary: Cohort A: Objective Response Rate (ORR) Assessed by Independent Central Review — 40.5 percentage of participants
Wound Healing
Primary: Wound Volume Reduction Rate (Unit: %) — 62.15; 65.04 percentage of baseline wound volume
Fragile X Syndrome · FXS · Fra(X) Syndrome
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 11; 8 Participants
Interaction, Adverse Herb-Drug · Diabetes Mellitus, Type 2
Primary: Metformin AUC — 59.6; 54.5; 57.3 mcg*hr/mL